@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAnr3oEk4Cf1UeR3LLPPY0M5cjGvViPLiktjKR6yDv1Ks> .
@prefix sub: <http://purl.org/np/RAnr3oEk4Cf1UeR3LLPPY0M5cjGvViPLiktjKR6yDv1Ks#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_3393> biolink:category biolink:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_3393>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00216>;
    rdfs:label "\"Eletriptan hydrobromide tablets are contraindicated in patients with:    Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina  [see Warnings and Precautions ( 5.1 )] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders  [see Warnings and Precautions ( 5.2 )] History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke  [see Warnings and Precautions ( 5.4 )] Peripheral vascular disease  [see Warnings and Precautions ( 5.5 )] Ischemic bowel disease  [see Warnings and Precautions ( 5.5 )] Uncontrolled hypertension  [see Warnings and Precautions ( 5.8 )] Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 1 [see Drug Interactions ( 7.1 )] Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen)  [see Warnings and Precautions ( 5.9 )] Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir  [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )]   History of coronary artery disease (CAD) or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Within 24 hours of treatment with another 5-HT 1 4 Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) ( 4 Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir ( 4\"";
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00216> biolink:category biolink:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "h017BHK2/BDbZ44JW1fNEqZlnvkr63eKV0F/C3hiP2mMUMmTUcOGpGiZfq6MHSY2JR3BDtXStpdlRnSrwnAqxm6QkQ+ul+h5PfLJqr/h6rRXK7asaRhVOhrYPk8KgPoz4IDpxEYLP6xUCXo5OrMjYakToQ+BRUJctp61c+nkKJ4=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T13:13:02.533+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}